A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C

Hepatology

Volumn 31, Issue 3, 2000, Pages 726-729

  Martinot Peignoux, Michèle ^a   Boyer, Nathalie ^a   Le Breton, Véronique ^a   Le Guludec, Gaëlle ^a   Castelnau, Corinne ^a   Akremi, Raoudha ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; DIAGNOSTIC ACCURACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

EID: 0034003872     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310324     Document Type: Article

References (22)

1. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquen M, Degott C, et al. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. HEPATOLOGY 1995;22:1050-1056.
2. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchalelle V, Auperin A, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214-223.
3. Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. HEPATOLOGY 1997;20(Suppl):123S-127S.
4. Kolberg JA, Sanchez-Pescador R, Detmer J, Collins M, Sheridan P, Neuwald P, Wilber J, et al. Branched DNA quantitation of hepatitis C viral RNA in patients sera. In: Groupe Français d'Études Moléculaires des hépatites virales (GEMHEP) ed. Hepatitis C Virus: New Diagnostic Tools. Paris: John Libbey Eurotext, 1994;57-70.
5. Detmer J, Lagier R, Flynn J, Zayat C, Kolberg J, Collins M, Urdea M, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all genotypes by using branched-DNA technology. J Clin Microbiol 1996;34:901-907.
6. Pawlotsky JM, Martinot-Peignoux M, Poveda JD, Bastie A, Le Breton V, Darthuy F, Remeri J, et al. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. J Virol Methods 1999;79:227-235.
7. Roth WK, Lee JH, Ruster B, Zeuzem S. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996;34:261-264.
8. Albadalejo J, Alonzo R, Antinozzi R, Bogard M, Bourgault AM, Colucci G, Fenner T, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 1998;36:862-865.
9. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre JC. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999;37:1567-1569.
10. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomized trial of Interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus Interferon alfa 2b plus placebo for 48 weeks or for 24 weeks for treatment of chronic infection with hepatitis C. Lancet 1998;352:1426-1432.
11. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
12. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin as for the treatment of relapse chronic hepatitis C. N Engl J Med 1998;339:1494-1498.
13. EASL International Consensus Conference on Hepatitis C. Consensus statement. Paris, February 26-28, 1999. J Hepatol 1999;30:956-961.
14. Tong MJ, Blatt LM, McHuchinson JG, Co RL, Conrad A. Prediction of response to interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. HEPATOLOGY 1997;6:1640-1645.
15. Pockros PJ, Bain VG, Hunter EB, Conrard A, Balart A, Hollinger FB, Albert D, et al. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. J Viral Hepat 1999;6:145-150.
16. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
17. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, Payan C, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepat 1999;6:435-443.
18. Lau JYN, Simmonds P, Urdea M. Implication of variations of conserved regions of hepatitis C virus genome. Lancet 1995;346:425-426.
19. Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus load among individuals infected with hepatitis C virus (HCV) genotypes 1,2, and 3 by Quantiplex HCV RNA assay version 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997;35:187-192.
20. Lunel F, Cresta P, Vitour D, Payan C, Dumont B, Frangeul L, Reboul D, et al. Comparative evaluation of hepatitis C virus RNA quantitation by bDNA, NASBA, and Monitor assays. HEPATOLOGY 1999;29:528-535.
21. Gretch DR, De la Rosa C, Carithers Jr RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995;123:321-329.
22. Fang JWS, Albrecht JK, Jacobs S, Lau JYN. Quantification of serum hepatitis C virus RNA. HEPATOLOGY 1999;29:997-998.